Medicenna Therapeutics (TSE:MDNA) Reaches New 1-Year Low – Here’s Why

Medicenna Therapeutics Corp. (TSE:MDNA) shares hit a new 52-week low on Tuesday . The stock traded as low as C$0.41 and last traded at C$0.41, with a volume of 65291 shares traded. The stock had previously closed at C$0.41.

Medicenna Therapeutics Price Performance

The stock has a 50 day simple moving average of C$0.52 and a two-hundred day simple moving average of C$0.77. The firm has a market cap of C$33.79 million, a PE ratio of -2.70 and a beta of 2.89. The company has a debt-to-equity ratio of 3.30, a quick ratio of 4.65 and a current ratio of 2.68.

Medicenna Therapeutics (TSE:MDNA) last issued its quarterly earnings data on Thursday, April 30th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. Sell-side analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.